Dorsal Root Ganglion Stimulation - 06/05/22
Doi : 10.1016/j.pmr.2022.02.005
Steven T. Potter, DO, MS a, ⁎ 
, Sean Welch, MD a, Faye Tata, DO a, Seth Probert, DO a, Ameet Nagpal, MD, MS, MEd b
, Sean Welch, MD a, Faye Tata, DO a, Seth Probert, DO a, Ameet Nagpal, MD, MS, MEd b a Department of Rehabilitation Medicine, UT Health San Antonio, Mail Code 7798, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA
b Department of Anesthesiology, UT Health San Antonio, Mail Code 7798, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA
∗Corresponding author.
Riassunto |
The recent development and Food and Drug Administration approval in 2016 of dorsal root ganglion stimulation is a relatively new and novel form of target neuromodulation that promises improved outcomes compared with the current standard of care. Current literature is limited and dependent on industry evaluation. Future independent investigation will help clarify existing data and refine techniques to improve safety, effectiveness, and expand application.
Il testo completo di questo articolo è disponibile in PDF.Keywords : Dorsal root ganglion stimulation, Neuromodulation, FDA approval
Mappa
© 2022
Elsevier Inc. Tutti i diritti riservati.
Vol 33 - N° 2
P. 359-378 - Maggio 2022 Ritorno al numero
Articolo precedente
- Spinal Cord Stimulation : A Physiatric Perspective
- Mehul J. Desai, Ryan Aschenbrener, Eduardo J. Carrera, Nirguna Thalla
- Peripheral Nerve Stimulation for Chronic Pain and Migraine : A Review
- Samantha C. Erosa, Roya S. Moheimani, Jessica C. Oswald, Joel P. Castellanos, Mickey E. Abraham, Nathaniel M. Schuster
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?